{
    "clinical_study": {
        "@rank": "29951", 
        "arm_group": [
            {
                "arm_group_label": "Aripiprazole 8-week group", 
                "arm_group_type": "Experimental", 
                "description": "Adjunctive aripiprazole 8-week treatment"
            }, 
            {
                "arm_group_label": "Aripiprazole 6-week group", 
                "arm_group_type": "Active Comparator", 
                "description": "Adjunctive aripiprazole 6-week treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators hypothesized that combined pharmacotherapy using adjunctive aripiprazole\n      of standard antidepressants would be associated with improved depression response in Major\n      depressive disorder, especially in Quality of life.\n\n      The investigators compare the mean changes in the quality of life between before add-on and\n      8 weeks treatment of aripiprazole and between before add-on and 6 weeks treatment of\n      aripiprazole."
        }, 
        "brief_title": "Aripiprazole (Abilify\u00ae) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "detailed_description": {
            "textblock": "Previous study about quality of life measurement in patients with depression have been\n      reported that quality of life have to be measured irrespective with the severity of\n      depression because quality of life has some other aspect to depression.The investigators\n      have designed a 6-week single blinded study with flexible dose aripiprazole augmentation,\n      ranging from 2.5mg to maximum 20 mg (15mg for patients on fluoxetine or paroxetine), in\n      patients who responded inadequately (a score of >18 on the MADRS) to first-line\n      antidepressant pharmacotherapy. The investigators compare the mean changes from in the\n      quality of life at 8 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age : 18-65\n\n          -  Patients with major depressive disorder according to DSM-IV criteria that have lasted\n             >8 weeks\n\n          -  MADRS total score of 18 or higher\n\n          -  Patients who responded inadequately (a score of >18 on the MADRS) to first-line\n             antidepressant treatment of 4 week duration\n\n          -  Current use of standard antidepressant treatment  in monotherapy or combination of 2\n             antidepressants  : escitalopram (10 - 20mg/d), fluoxetine(20 - 40mg/d), paroxetine\n             CR(25 - 50mg/d), sertraline(100 - 150mg/d), mirtazapine (15 - 45mg/d), duloxetine (30\n             - 60mg/d) or venlafaxine ER(150-225mg/d)\n\n        Exclusion Criteria:\n\n          -  Past history of hypersensitivity to aripiprazole\n\n          -  Primary diagnosis of MDD with psychotic feature, bipolar disorder, schizophrenia,\n             schizoaffective disorder, other psychotic disorder or anxiety disorder, a history of\n             alcohol/ drug abuse within the past 12 months, or a diagnosis of dementia\n\n          -  Clinically significant current Axis II (DSM-IV-TR) diagnosis\n\n          -  A significant risk of suicide corroborated by a score of \u22655 on item 10(suicidal\n             thoughts) on the MADRS scale or by clinical judgment of the investigator\n\n          -  Pregnancy or in breast-feeding\n\n          -  Presence of a serious medical illness including cardiac, hepatic, renal, respiratory,\n             endocrinologic, neurologic, or hematologic disease or physical disorder judged to\n             significantly affect central nervous system function\n\n          -  Patients taking antipsychotics, mood stabilizer or any psychotropic medications\n             besides antidepressants, except benzodiazepines or beta blockers or hypnotics\n\n          -  Patients with past treatment failures of aripiprazole"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01696617", 
            "org_study_id": "031-KOC-1108i"
        }, 
        "intervention": [
            {
                "arm_group_label": "Aripiprazole 8-week group", 
                "intervention_name": "Aripiprazole 6-week group", 
                "intervention_type": "Drug", 
                "other_name": "Abilify\u00ae"
            }, 
            {
                "arm_group_label": "Aripiprazole 6-week group", 
                "intervention_name": "Aripiprazole 8-week group", 
                "intervention_type": "Drug", 
                "other_name": "Abilify\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Aripiprazole"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 5, 2013", 
        "location": {
            "contact": {
                "email": "aym@snu.ac.kr", 
                "last_name": "Yong Min Ahn, MD, Ph.D.", 
                "phone": "82 2 2072 0710"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-744"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "investigator": {
                "last_name": "Yong Min Ahn, MD, Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Aripiprazole (Abilify\u00ae) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder", 
        "other_outcome": [
            {
                "measure": "Hamilton Rating Scale for Depression", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline at 8 weeks"
            }, 
            {
                "measure": "Clinical Global Impression-severity, Clinical Global Impression-Improvement", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline at 8 weeks"
            }, 
            {
                "measure": "Beck Depression Inventory", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline at 8 weeks"
            }, 
            {
                "measure": "Inventory of Depressive Symptomatology Self-Report Scale", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline at 8 weeks"
            }, 
            {
                "measure": "Drug - Induced Extrapyramidal Symptoms Scale", 
                "safety_issue": "Yes", 
                "time_frame": "Change from Baseline at 8 weeks"
            }, 
            {
                "measure": "The Liverpool University Neuroleptic Side Effect Rating Scale", 
                "safety_issue": "Yes", 
                "time_frame": "Change from Baseline at 8 weeks"
            }, 
            {
                "measure": "Short From-36 Health survey", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline at 8 weeks"
            }
        ], 
        "overall_contact": {
            "email": "npeunyoung@gmail.com", 
            "last_name": "Eun Young Kim, MD", 
            "phone": "82 2 2072 2456"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Yong Min Ahn, MD. Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Quality of Life Scale (QOLS)", 
            "safety_issue": "No", 
            "time_frame": "Change from Baseline at 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01696617"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Hospital", 
            "investigator_full_name": "Yong Min Ahn", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Montgomery-\u00c5sberg Depression Rating Scale", 
            "safety_issue": "No", 
            "time_frame": "Change from Baseline at 8 weeks"
        }, 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}